Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol H6Q-MC-S034(a) randomized, double-blind, phase 2 study of pemetrexed + carboplatin + bevacizumab + enzastaurin versus pemetrexed + carboplatin + bevacizumab + placebo in chemonaive patients with stage IIIB or IV non-small cell lung cancer

Next Previous
X
Search
Trial Profile

Protocol H6Q-MC-S034(a) randomized, double-blind, phase 2 study of pemetrexed + carboplatin + bevacizumab + enzastaurin versus pemetrexed + carboplatin + bevacizumab + placebo in chemonaive patients with stage IIIB or IV non-small cell lung cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzastaurin (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 21 Jan 2011 Primary endpoint 'Progression-free-survival-duration' has not been met
    • 27 Sep 2010 Results published in the Journal of Thoracic Oncology.
    • 30 May 2009 Results reported at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top